Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435849 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02435849 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 80 participants.
The verdict
NCT02435849, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
Interventions
- BIOLOGICAL CTL019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-04-08 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02435849
The ClinicalTrials.gov registry entry for NCT02435849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTL019 is the first listed.
NCT02435849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02435849 about?
NCT02435849 is a clinical study titled "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients". This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
What is the current status of trial NCT02435849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2015-04-08. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT02435849?
The interventions under investigation include: CTL019 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02435849?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.